Kite Pharma +35% following non-Hodgkin's lymphoma drug study result

|About: Kite Pharma (KITE)|By:, SA News Editor

Kite Pharma (NASDAQ:KITE) +34.5% AH after announcing positive results in a clinical study of patients receiving Kite's treatment for non-Hodgkin's lymphoma.

The clinical trial funded by Kite and conducted by the Surgery Branch of the National Cancer Institute found that in 12 of 13 evaluable patients with advanced B-cell malignancies receiving Kite's anti-CD19 CAR T cell therapy resulted in complete remission in eight patients and partial remission in four patients.

Based on the study, Kite says it plans to file an Investigational New Drug Application during Q4.